News
2don MSN
Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...
Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.
This was the stock's second consecutive day of gains.
1d
The Mobile Rundown on MSNShe Helped Build a Startup That’s Changing How We Treat DiseaseJanice Chen co-founded Mammoth Biosciences after inventing a powerful gene detection tool in grad school. Now she's helping ...
Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, ...
For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Wu draws more small donations from city residents while Kraft attracts larger contributions and significant out-of-state ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results